Issue Date: January 2, 2017
Asahi Glass to buy CMC Biologics
Japan’s Asahi Glass has agreed to acquire CMC Biologics, a contract manufacturer of biologic drugs, for $510 million. The purchase continues the glass and chemical maker’s push into biologic drug manufacturing. In August, Asahi announced plans to buy the German contract manufacturer Biomeva. Private equity-owned CMC operates plants in Copenhagen, Seattle, and Berkeley, Calif., that produce biologic drug ingredients in mammalian and microbial hosts. It has about 530 employees.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society